-VX-150 was generally well tolerated and showed statistically significant relief of acute pain compared to placebo; study included an active reference arm of the opioid pain medicine ...
-Results from Part A of Phase 3 study in people with a mutation that results in minimal cystic fibrosis transmembrane conductance regulator (CFTR) protein function do not support continuation of the ...
- Phase 2 study of VX-814 in patients with alpha-1 antitrypsin deficiency discontinued based upon safety and pharmacokinetic data - - Phase 2 study of VX-864 continues to enroll and dose patients; ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results